{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:44:20Z","timestamp":1791582260351,"version":"4.3.4"},"reference-count":64,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI105185"],"award-info":[{"award-number":["R01AI105185"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2022,6,21]]},"abstract":"<jats:p>\n            Point mutations in the\n            <jats:italic>rrs<\/jats:italic>\n            gene and the\n            <jats:italic>eis<\/jats:italic>\n            promoter are known to confer resistance to the second-line injectable drugs (SLIDs) amikacin (AMK), capreomycin (CAP), and kanamycin (KAN). While mutations in these canonical genes confer the majority of SLID resistance, alternative mechanisms of resistance are not uncommon and threaten effective treatment decisions when using conventional molecular diagnostics.\n          <\/jats:p>","DOI":"10.1128\/aac.02075-21","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T13:00:47Z","timestamp":1652101247000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":16,"title":["Distribution of Common and Rare Genetic Markers of Second-Line-Injectable-Drug Resistance in Mycobacterium tuberculosis Revealed by a Genome-Wide Association Study"],"prefix":"10.1128","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3442-8334","authenticated-orcid":true,"given":"Derek","family":"Conkle-Gutierrez","sequence":"first","affiliation":[{"name":"Laboratory for Pathogenesis of Clinical Drug Resistance and Persistence (LPCDRP), Biomedical Informatics Research Center, Division of Epidemiology, School of Public Health, San Diego State University, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin","family":"Kim","sequence":"additional","affiliation":[{"name":"Laboratory for Pathogenesis of Clinical Drug Resistance and Persistence (LPCDRP), Biomedical Informatics Research Center, Division of Epidemiology, School of Public Health, San Diego State University, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Ramirez-Busby","sequence":"additional","affiliation":[{"name":"Laboratory for Pathogenesis of Clinical Drug Resistance and Persistence (LPCDRP), Biomedical Informatics Research Center, Division of Epidemiology, School of Public Health, San Diego State University, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7674-305X","authenticated-orcid":true,"given":"Samuel J.","family":"Modlin","sequence":"additional","affiliation":[{"name":"Laboratory for Pathogenesis of Clinical Drug Resistance and Persistence (LPCDRP), Biomedical Informatics Research Center, Division of Epidemiology, School of Public Health, San Diego State University, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Mansj\u00f6","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Public Health Agency of Sweden, Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Werngren","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Public Health Agency of Sweden, Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leen","family":"Rigouts","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Antwerp University (UA), Antwerp, Belgium"},{"name":"Mycobacteriology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine (ITM), Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven E.","family":"Hoffner","sequence":"additional","affiliation":[{"name":"Laboratory for Pathogenesis of Clinical Drug Resistance and Persistence (LPCDRP), Biomedical Informatics Research Center, Division of Epidemiology, School of Public Health, San Diego State University, San Diego, California, USA"},{"name":"Department of Global Public Health, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3648-9384","authenticated-orcid":true,"given":"Faramarz","family":"Valafar","sequence":"additional","affiliation":[{"name":"Laboratory for Pathogenesis of Clinical Drug Resistance and Persistence (LPCDRP), Biomedical Informatics Research Center, Division of Epidemiology, School of Public Health, San Diego State University, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","volume-title":"Global tuberculosis report 2021.","author":"World Health Organization.","year":"2021","unstructured":"World Health Organization. 2021. Global tuberculosis report 2021. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_3_2","volume-title":"Global tuberculosis report 2019.","author":"World Health Organization.","year":"2019","unstructured":"World Health Organization. 2019. Global tuberculosis report 2019. Document number WHO\/CDS\/TB\/2019.15. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_4_2","volume-title":"Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis.","author":"World Health Organization.","year":"2014","unstructured":"World Health Organization. 2014. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Document number WHO\/HTM\/TB\/2014.11. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics3030317"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr109"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00044812"},{"key":"e_1_3_2_8_2","volume-title":"Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis.","author":"World Health Organization.","year":"2018","unstructured":"World Health Organization. 2018. Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis. Document number WHO\/CDS\/TB\/2018.18. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_9_2","volume-title":"Rapid communication: key changes to the treatment of drug-resistant tuberculosis.","author":"World Health Organization.","year":"2019","unstructured":"World Health Organization. 2019. Rapid communication: key changes to the treatment of drug-resistant tuberculosis. Document number WHO\/CDS\/TB\/2019.26. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.05274-11"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-017-0029-0"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmyco.2015.09.001"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01299-16"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00851-09"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2018.09.023"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0907925106"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks178"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1039\/c2mb25341k"},{"key":"e_1_3_2_19_2","volume-title":"Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance.","author":"World Health Organization.","year":"2021","unstructured":"World Health Organization. 2021. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. World Health Organization, Geneva, Switzerland. https:\/\/www.who.int\/publications\/i\/item\/9789240028173."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.2.571-577.2005"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00626-13"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06634-y"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139414"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2016.08.049"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02701-13"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2006.05.044"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav5912"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01164-21"},{"key":"e_1_3_2_29_2","first-page":"2713","article-title":"The roles of rpsL, rrs, and gidB mutations in predicting streptomycin-resistant drugs used on clinical Mycobacterium tuberculosis isolates from Hebei Province, China","volume":"12","author":"Wang Y","year":"2019","unstructured":"Wang Y, Li Q, Gao H, Zhang Z, Liu Y, Lu J, Dai E. 2019. The roles of rpsL, rrs, and gidB mutations in predicting streptomycin-resistant drugs used on clinical Mycobacterium tuberculosis isolates from Hebei Province, China. Int J Clin Exp Pathol 12:2713\u20132721.","journal-title":"Int J Clin Exp Pathol"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.01838"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148676"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0207605"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02191-12"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10110-6"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-019-5615-3"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkt751"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2013.10.031"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq973"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2005.04.015"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076765"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152926"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04438-14"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033275"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.2010.07218.x"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01347-17"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/mSystems.00673-21"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq1019"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00062-6"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1101\/gr.128678.111"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2878"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-15-308"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0488"},{"key":"e_1_3_2_53_2","volume-title":"Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs.","author":"World Health Organization.","year":"2008","unstructured":"World Health Organization. 2008. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_54_2","volume-title":"Technical report on critical concentrations for TB drug susceptibility testing of medicines used in the treatment of drug-resistant TB.","author":"World Health Organization.","year":"2018","unstructured":"World Health Organization. 2018. Technical report on critical concentrations for TB drug susceptibility testing of medicines used in the treatment of drug-resistant TB. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1385\/1-59259-147-7:019"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2015.42"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-017-3687-5"},{"key":"e_1_3_2_58_2","doi-asserted-by":"crossref","unstructured":"Ramirez-Busby SM Elghraoui A Kim YB Valafar F. 2018. PBHoover and CigarRoller: a method for confident haploid variant calling on legacy Pacific Biosciences data and its application to heterogeneous population analysis. bioRxiv. https:\/\/doi.org\/10.1101\/360370.","DOI":"10.1101\/360370"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1101\/gr.215087.116"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/27.11.2369"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.1923"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1101\/gr.129684.111"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2012.02.010"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2010.09.006"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8%3C857::AID-SIM777%3E3.0.CO;2-E"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.02075-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.02075-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T14:49:27Z","timestamp":1655822967000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.02075-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6,21]]}},"alternative-id":["10.1128\/aac.02075-21"],"URL":"https:\/\/doi.org\/10.1128\/aac.02075-21","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,21]]},"assertion":[{"value":"2021-11-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02075-21"}}